IL254520A0 - Heterocyclic tricyclic compounds for use as tnf inhibitors - Google Patents
Heterocyclic tricyclic compounds for use as tnf inhibitorsInfo
- Publication number
- IL254520A0 IL254520A0 IL254520A IL25452017A IL254520A0 IL 254520 A0 IL254520 A0 IL 254520A0 IL 254520 A IL254520 A IL 254520A IL 25452017 A IL25452017 A IL 25452017A IL 254520 A0 IL254520 A0 IL 254520A0
- Authority
- IL
- Israel
- Prior art keywords
- tnf
- inhibitors
- heterocyclic compounds
- compounds useful
- tricyclic heterocyclic
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562134779P | 2015-03-18 | 2015-03-18 | |
| PCT/US2016/022738 WO2016149437A1 (en) | 2015-03-18 | 2016-03-17 | Tricyclic heterocyclic compounds useful as inhibitors of tnf |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL254520A0 true IL254520A0 (en) | 2017-11-30 |
Family
ID=55640933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL254520A IL254520A0 (en) | 2015-03-18 | 2017-09-15 | Heterocyclic tricyclic compounds for use as tnf inhibitors |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10308652B2 (enExample) |
| EP (1) | EP3271361B1 (enExample) |
| JP (1) | JP6793658B2 (enExample) |
| KR (1) | KR102630010B1 (enExample) |
| CN (1) | CN107635992B (enExample) |
| AU (1) | AU2016233289A1 (enExample) |
| BR (1) | BR112017019731A2 (enExample) |
| CA (1) | CA2982446A1 (enExample) |
| EA (1) | EA032314B1 (enExample) |
| ES (1) | ES2797685T3 (enExample) |
| IL (1) | IL254520A0 (enExample) |
| MX (1) | MX2017011433A (enExample) |
| SG (1) | SG11201707471RA (enExample) |
| WO (1) | WO2016149437A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017011577A (es) | 2015-03-18 | 2017-10-26 | Bristol Myers Squibb Co | Compuestos heterociclicos utiles como inhibidores de factor de necrosis tumoral (tnf). |
| CA2980159A1 (en) | 2015-03-18 | 2016-09-22 | Bristol-Myers Squibb Company | Substituted tricyclic heterocyclic compounds |
| UY36628A (es) | 2015-04-17 | 2016-11-30 | Abbvie Inc | Indazolonas como moduladores de la señalización de tnf |
| US20160304496A1 (en) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Indazolones as modulators of tnf signaling |
| WO2016168641A1 (en) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Tricyclic modulators of tnf signaling |
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| CN108137609B (zh) | 2015-08-03 | 2021-07-16 | 百时美施贵宝公司 | 用作TNFα的调节剂的环状化合物 |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
| JP7121033B2 (ja) | 2017-03-15 | 2022-08-17 | ユーシービー バイオファルマ エスアールエル | Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4391806A (en) * | 1982-07-12 | 1983-07-05 | The Dow Chemical Company | Substituted tetrahydropyridazino-(1,6-A)benzimidazoles and use as bronchodilators |
| EP0963371B1 (en) | 1997-02-25 | 2003-05-02 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase |
| DE60024480T2 (de) * | 1999-10-27 | 2006-07-27 | Novartis Ag | Thiazol und imidazo[4,5-b]pyridin verbindungen und ihre verwendung als pharmazeutika |
| CN1633434A (zh) | 2002-01-31 | 2005-06-29 | 第一制药株式会社 | 咪唑并[1,2－a]吡啶衍生物 |
| AU2003298839A1 (en) | 2002-12-03 | 2004-06-23 | Isis Pharmaceuticals, Inc. | Benzimidazoles and analogs thereof as antivirals |
| US20050124638A1 (en) | 2003-12-08 | 2005-06-09 | Swayze Eric E. | Benzimidazoles and analogs thereof as antivirals |
| EP2209785A1 (en) | 2007-10-05 | 2010-07-28 | S*BIO Pte Ltd | 2-morpholinylpurines as inhibitors of pi3k |
| CN101717397B (zh) | 2008-10-09 | 2012-11-28 | 中国科学院上海药物研究所 | 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物 |
| US8691187B2 (en) | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
| WO2012148550A1 (en) | 2011-02-25 | 2012-11-01 | Myrexis, Inc. | Prodrugs of therapeutic compounds |
| EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| TR201807207T4 (tr) | 2012-06-11 | 2018-06-21 | Ucb Biopharma Sprl | Tnf-alfa modüle edici benzimidazol bileşikleri. |
| JP6259823B2 (ja) * | 2012-07-13 | 2018-01-10 | ユーシービー バイオファルマ エスピーアールエル | Ｔｎｆ活性の調節物質としてのイミダゾピリジン誘導体 |
| GB201212513D0 (en) | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
| BR112015009649A2 (pt) * | 2012-11-07 | 2017-07-04 | Hoffmann La Roche | composto de triazolo |
| ES2529865B8 (es) * | 2013-07-25 | 2016-01-22 | Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz (Fibhulp) | USO DE COMPUESTOS DERIVADOS DE SALES DE PIRIDAZINO[1',6':1,2]PIRIDO[3,4-b]INDOLINIO COMO AGENTES ANTIINFLAMATORIOS |
| GB201321746D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321741D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321735D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321739D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| JP6469692B2 (ja) | 2013-12-09 | 2019-02-13 | ユーシービー バイオファルマ エスピーアールエル | Ｔｎｆ活性のモジュレーターとしてのイミダゾピリジン誘導体 |
| GB201321742D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321737D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321744D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| WO2015086523A1 (en) | 2013-12-09 | 2015-06-18 | Ucb Biopharma Sprl | Fused bicyclic heteroaromatic derivatives as modulators of tnf activity |
| GB201321745D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321743D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321738D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| CA2963639C (en) | 2014-10-06 | 2023-07-04 | Signal Pharmaceuticals, Llc | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
| MX2017011577A (es) | 2015-03-18 | 2017-10-26 | Bristol Myers Squibb Co | Compuestos heterociclicos utiles como inhibidores de factor de necrosis tumoral (tnf). |
| CA2980159A1 (en) | 2015-03-18 | 2016-09-22 | Bristol-Myers Squibb Company | Substituted tricyclic heterocyclic compounds |
| WO2016168641A1 (en) * | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Tricyclic modulators of tnf signaling |
| EP3292127A1 (en) * | 2015-05-04 | 2018-03-14 | Actelion Pharmaceuticals Ltd | Tricyclic piperidine compounds |
-
2016
- 2016-03-17 JP JP2017549093A patent/JP6793658B2/ja active Active
- 2016-03-17 AU AU2016233289A patent/AU2016233289A1/en not_active Abandoned
- 2016-03-17 BR BR112017019731-6A patent/BR112017019731A2/pt not_active Application Discontinuation
- 2016-03-17 US US15/558,708 patent/US10308652B2/en active Active
- 2016-03-17 EP EP16712646.5A patent/EP3271361B1/en active Active
- 2016-03-17 MX MX2017011433A patent/MX2017011433A/es unknown
- 2016-03-17 EA EA201792025A patent/EA032314B1/ru not_active IP Right Cessation
- 2016-03-17 WO PCT/US2016/022738 patent/WO2016149437A1/en not_active Ceased
- 2016-03-17 CN CN201680025154.3A patent/CN107635992B/zh active Active
- 2016-03-17 CA CA2982446A patent/CA2982446A1/en not_active Abandoned
- 2016-03-17 SG SG11201707471RA patent/SG11201707471RA/en unknown
- 2016-03-17 ES ES16712646T patent/ES2797685T3/es active Active
- 2016-03-17 KR KR1020177029450A patent/KR102630010B1/ko active Active
-
2017
- 2017-09-15 IL IL254520A patent/IL254520A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017019731A2 (pt) | 2018-05-22 |
| EP3271361A1 (en) | 2018-01-24 |
| CN107635992A (zh) | 2018-01-26 |
| KR102630010B1 (ko) | 2024-01-25 |
| EP3271361B1 (en) | 2020-04-22 |
| AU2016233289A1 (en) | 2017-11-09 |
| KR20170129811A (ko) | 2017-11-27 |
| EA032314B1 (ru) | 2019-05-31 |
| US20180111937A1 (en) | 2018-04-26 |
| JP6793658B2 (ja) | 2020-12-02 |
| EA201792025A1 (ru) | 2018-01-31 |
| JP2018508554A (ja) | 2018-03-29 |
| CN107635992B (zh) | 2020-05-22 |
| WO2016149437A1 (en) | 2016-09-22 |
| US10308652B2 (en) | 2019-06-04 |
| CA2982446A1 (en) | 2016-09-22 |
| ES2797685T3 (es) | 2020-12-03 |
| MX2017011433A (es) | 2017-11-10 |
| SG11201707471RA (en) | 2017-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME03740B (me) | Jedinjenja indol karboksamida korisna kao inhibitori kinaze | |
| ZA201800716B (en) | Heterocyclic compounds useful as modulators of tnf alpha | |
| ZA201706710B (en) | Heterocyclic compounds as lsd1 inhibitors | |
| PL3371190T3 (pl) | Związki heterocykliczne jako inhibitory pi3k-gamma | |
| IL255817A (en) | Synthesis of heterocyclic compounds | |
| ZA201700304B (en) | Spirocycloheptanes as inhibitors of rock | |
| IL254520A0 (en) | Heterocyclic tricyclic compounds for use as tnf inhibitors | |
| IL279949A (en) | Heterocyclic MCT4 inhibitors | |
| IL255750A (en) | Heterocyclic compounds as kinase inhibitors | |
| ZA201605586B (en) | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | |
| IL254430A0 (en) | Heterocyclic compounds are useful as TNF inhibitors | |
| IL254424A0 (en) | Disubstituted heterocyclic tricyclic compounds | |
| IL257501B (en) | Compounds containing heterocyclic tricyclic compounds |